GENinCode plc (AIM: GENI.L), a genetics company focused on the prevention of cardiovascular disease (“CVD”) and the early detection of ovarian cancer, announced on 14 February 2025 the launch of a fundraising comprising a Placing and Subscription to raise a minimum of £4.0 million.
The Company also announced on 14 February 2025 that it intended to carry out a separate Retail Offer via RetailBook (the “Retail Offer” together with the Placing and Subscription, being the “Fundraising”). The Company announced on 14 February 2025 that it had conditionally raised £4 million through the Placing and Subscription.
The Company confirms that the Retail Offer closed at 5.00 p.m. on 17 February 2025 and that it has received conditional subscriptions for 1,809,508 new Ordinary Shares at the Issue Price of 3.7 pence per share in the Retail Offer.
Following the close of the Retail Offer, the Company has conditionally raised gross proceeds of approximately £4.1 million at the Issue Price via the Fundraising. The Company will therefore allot and issue an aggregate of 109,917,616 New Ordinary Shares in connection with the Fundraising.
Each of the Retail Offer, the Placing and the Subscription is conditional upon the fundraising resolutions being duly passed without amendment at a General Meeting of the Company to be held on 3 March 2025 and Admission becoming effective at 8:00 am on or around 4 March 2025 (or such later date as the Company and its advisors may agree, but not later than 31 March 2025).
Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the launch announcement.
Admission and Total Voting Rights
Application will be made to the London Stock Exchange for 109,917,616 New Ordinary Shares (comprising 88,040,541 Placing Shares, 20,067,567 Subscription Shares and 1,809,508 Retail Shares) to be admitted to trading on AIM. Admission is expected to take place and dealings in the New Ordinary Shares are expected to commence at 8.00 a.m. on or around 4 March 2025, at which time it is also expected that the New Ordinary Shares will be enabled for settlement in CREST.
Immediately following Admission, the issued share capital of the Company is expected to comprise 286,882,042 Ordinary Shares. Each Ordinary Share has one voting right and no Ordinary Shares are held in treasury. Accordingly, immediately following Admission, the total number of voting rights in the Company will be 286,882,042. From Admission, this figure may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.
Enquiries:
|
GENinCode Plc |
or via Walbrook PR |
|
Matthew Walls, CEO Paul Foulger, CFO |
